DUSP1 and metastatic melanoma: In primary and metastatic melanoma, DUSP1 knockdown and pharmacologic DUSP1 inhibition decreased MAPK-inhibitor resistance and sensitized melanoma cells to BRAF and MEK inhibitors.164